Psivida wins technology award

By Melissa Trudinger
Thursday, 15 July, 2004

Nanotechnology company Psivida (ASX: PSD) has had its research applying its BioSilicon technology to drug delivery, diagnostics, orthopaedics and tissue engineering recognised with a 2004 Excellence in Research Award from US consulting group Frost & Sullivan.

Frost & Sullivan announced the award in a recently released study focusing on nanomedicine.

Related News

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...

Content from other channels on our network

Neuroscientists propose clinical definition for brain fog in menopause

National Pain Alliance launched to advocate for chronic pain

Sexual misconduct findings added to public register under "landmark reforms"

Australia invests further $14.6 million in national allergy research

Can seasonal influenza vaccination prime the immune system for future strains?

AI won’t restart your plant: Why practical skills matter more than ever

POSCO Holdings steps up HILT CRC partnership

Hazer and KBR complete commercial-scale hydrogen plant design

Calibration explained: principles, processes and modern reporting

Foodmach invests in A&RT

Six on the shelf: on-the-go protein, ready-to-cook veggies and more

What can food manufacturers learn from viral food trends?

Lion 'flicks the switch' to electric at Speight's Brewery

NZ Winegrowers calls for a White Wine Emoji

Nutrition claims compliance, fresh produce guide updated

All content Copyright © 2026 Westwick-Farrow Pty Ltd